Table: Sumitomo Pharma -9-MTH group results (IFRS)

Sumitomo Pharma

30/01/2026 06:32

Jan 30 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 9 months ended      9 months ended       Year to 
                Dec 31, 2025        Dec 31, 2024     Mar 31, 2026 
                   LATEST             YEAR-AGO          COMPANY   
                   RESULTS             RESULT          FORECAST   
  Sales            347.75              293.18           429.00    
                 (+18.6 pct)         (+24.7 pct)      (+7.6 pct)  
  Operating        109.77               13.23            98.00    
                (+730.0 pct)                         (+240.2 pct) 
  Pretax
  Net              107.68               21.22            92.00    
                (+407.5 pct)                         (+289.3 pct) 
  EPS Basic      271.03 yen           53.41 yen       231.57 yen  
  Ann Div                                NIL              NIL     
  -Q2 Div            NIL                 NIL                      
  -Q4 Div                                NIL              NIL     
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T